Lecanemab in Early Alzheimer's Disease.
作者信息
Valenzuela Michael J, Pascual-Leone Alvaro
机构信息
University of New South Wales, Sydney, NSW, Australia
Harvard Medical School, Boston, MA.
出版信息
N Engl J Med. 2023 Apr 27;388(17):1630. doi: 10.1056/NEJMc2301380.
PMID:37099352
Abstract
摘要
相似文献
1
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Apr 27;388(17):1630. doi: 10.1056/NEJMc2301380.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Apr 27;388(17):1630. doi: 10.1056/NEJMc2301380.
4
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Apr 27;388(17):1630-1631. doi: 10.1056/NEJMc2301380.
5
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Apr 27;388(17):1631. doi: 10.1056/NEJMc2301380.
6
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.Lecanemab Clarity AD：早期阿尔茨海默病的一项随机、双盲 3 期临床试验的生活质量结果。
J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123.
7
Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.CLARITY AD：早期阿尔茨海默病中lecanemab的III期试验亚洲区域分析
J Prev Alzheimers Dis. 2025 May;12(5):100160. doi: 10.1016/j.tjpad.2025.100160. Epub 2025 Apr 5.
8
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.一项针对早期阿尔茨海默病的仑卡奈单抗（抗 Aβ 原纤维抗体）的随机、双盲、2b 期概念验证临床试验。
Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
9
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.用lecanemab进行单克隆治疗轻度阿尔茨海默病：一项系统评价和荟萃分析。
Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.
10
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.早期阿尔茨海默病患者淀粉样蛋白正电子发射断层扫描和血浆生物标志物的群体药代动力学-药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27.
引用本文的文献
1
Exercise and Protection from Age-Related Cognitive Decline.运动与预防与年龄相关的认知能力下降。
Curr Top Behav Neurosci. 2024;67:263-280. doi: 10.1007/7854_2024_501.
2
Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.阿尔茨海默病的抗淀粉样蛋白治疗与淀粉样蛋白级联假说。
Int J Mol Sci. 2023 Sep 24;24(19):14499. doi: 10.3390/ijms241914499.
Zotero 插件